Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
HRMY 
Harmony Biosciences Holdings (HRMY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: HRMY (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $51.56
1 Year Target Price $51.56
| 5 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -34.07% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.84B USD | Price to earnings Ratio 12.21 | 1Y Target Price 51.56 |
Price to earnings Ratio 12.21 | 1Y Target Price 51.56 | ||
Volume (30-day avg) 9 | Beta 0.87 | 52 Weeks Range 26.47 - 41.61 | Updated Date 06/30/2025 |
52 Weeks Range 26.47 - 41.61 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.62 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 20.5% | Operating Margin (TTM) 30.45% |
Management Effectiveness
Return on Assets (TTM) 12.81% | Return on Equity (TTM) 24.71% |
Valuation
Trailing PE 12.21 | Forward PE 8.63 | Enterprise Value 1505158721 | Price to Sales(TTM) 2.47 |
Enterprise Value 1505158721 | Price to Sales(TTM) 2.47 | ||
Enterprise Value to Revenue 2.02 | Enterprise Value to EBITDA 6.33 | Shares Outstanding 57424300 | Shares Floating 44457334 |
Shares Outstanding 57424300 | Shares Floating 44457334 | ||
Percent Insiders 11.64 | Percent Institutions 92.91 |
Analyst Ratings
Rating 3 | Target Price 51.56 | Buy 3 | Strong Buy 5 |
Buy 3 | Strong Buy 5 | ||
Hold - | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Harmony Biosciences Holdings
Company Overview
History and Background
Harmony Biosciences Holdings, Inc. was founded in 2017. It focuses on developing and commercializing therapies for rare neurological disorders. The company's initial focus was on narcolepsy, and it has since expanded its pipeline.
Core Business Areas
- Narcolepsy: Development and commercialization of therapies for narcolepsy and other neurological disorders. Wakix is their primary product.
Leadership and Structure
Harmony Biosciences is led by a management team with experience in the pharmaceutical industry. The company has a board of directors providing strategic oversight.
Top Products and Market Share
Key Offerings
- Wakix (pitolisant): Wakix is a histamine-3 (H3) receptor antagonist/inverse agonist approved for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy. Wakix holds a significant market share in the treatment of narcolepsy. Competitors include Xyrem/Xywav (Jazz Pharmaceuticals) and Sunosi (Axsome).
Market Dynamics
Industry Overview
The market for narcolepsy treatments is growing, driven by increasing awareness and diagnosis rates. It is characterized by a mix of established and emerging therapies.
Positioning
Harmony Biosciences holds a strong position in the narcolepsy market with Wakix, offering a non-scheduled treatment option. Its competitive advantage lies in its unique mechanism of action and safety profile.
Total Addressable Market (TAM)
The TAM for narcolepsy treatments is estimated to be billions of dollars globally. Harmony Biosciences is well-positioned to capture a substantial portion of this market.
Upturn SWOT Analysis
Strengths
- Strong market position with Wakix
- Unique mechanism of action
- Non-scheduled treatment option
- Experienced management team
Weaknesses
- Reliance on a single product
- Limited pipeline
- Smaller size compared to major pharmaceutical companies
- Vulnerability to competition
Opportunities
- Expansion into new indications
- Geographic expansion
- Development of new therapies for narcolepsy and other neurological disorders
- Partnerships and acquisitions
Threats
- Competition from existing and new therapies
- Pricing pressures
- Regulatory challenges
- Patent expirations
Competitors and Market Share
Key Competitors
- JAZZ
- AVXL
- SKYX
Competitive Landscape
Harmony Biosciences differentiates itself through Wakix's unique mechanism of action and non-scheduled status. However, Jazz Pharmaceuticals holds a larger market share with Xyrem/Xywav, and other companies have emerging therapies.
Major Acquisitions
Zynerba Pharmaceuticals
- Year: 2023
- Acquisition Price (USD millions): 60
- Strategic Rationale: Expand pipeline with differentiated pharmaceutically-produced cannabidiol product candidate, Zygel (CBD gel), a potential new treatment option for patients suffering from Fragile X Syndrome (FXS).
Growth Trajectory and Initiatives
Historical Growth: Historical revenue and earnings growth data would be included here. This section requires access to real-time financial data sources. I cannot dynamically provide this information.
Future Projections: Analyst estimates for future revenue and earnings growth would be included here. This section requires access to real-time financial data sources. I cannot dynamically provide this information.
Recent Initiatives: Recent initiatives include expanding the Wakix label, developing new formulations, and exploring new therapeutic areas.
Summary
Harmony Biosciences is a focused biopharmaceutical company with a strong position in the narcolepsy market due to Wakix. Its revenue stream is heavily dependent on that one drug. Diversifying its pipeline is key for sustained growth. Competition from established players and emerging therapies poses a significant challenge.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings, Analyst reports, Market research reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is approximate and may vary based on the source. Financial data is not real-time and is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Harmony Biosciences Holdings
Exchange NASDAQ | Headquaters Plymouth Meeting, PA, United States | ||
IPO Launch date 2020-08-19 | President, CEO & Director Dr. Jeffrey M. Dayno M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 268 | |
Full time employees 268 | |||
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 1 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome (FXS), rare genetic disorder that causes inherited intellectual disability and autism spectrum disorder; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; and EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies (DEE). The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.